COVID-19 pandemic drives innovation in diabetes care

October 20, 2020

WASHINGTON--The COVID-19 pandemic has jumpstarted innovation in health care delivery and allowed for real-world testing of diabetes care models in unprecedented ways, according to a manuscript published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

For diabetes, which affects half a billion people worldwide, innovation has long been overdue. Currently, less than 50 percent of people with diabetes meet glycemic targets, which minimize the risk of complications. The COVID-19 pandemic has created an opportunity to rapidly implement and test models of diabetes care that were not possible before. These innovative models like telehealth have the potential to improve medical outcomes and the patient experience beyond the pandemic.

"We need to change the way we provide care, considering that outcomes of people with diabetes have not improved over the last decade," said task force chair Robert A. Gabbay, M.D., Ph.D., Chief Scientific and Medical Officer of the American Diabetes Association in Arlington, Va., and formerly Chief Medical Officer of the Joslin Diabetes Center in Boston, Mass. "Given the dual pandemics of COVID-19 and diabetes, adoption of these innovations has accelerated in the hopes of creating a 'new normal' and improvements in the care we provide for people with diabetes."

In 2018, the Endocrine Society convened a task force to examine and promote innovative models of care in diabetes. In this perspective, the members of the task force review several models of care including telemedicine, eConsultations and Project Echo - a global tele-mentoring program. They also cover team-based care, pharmacist-led care and the transition from pediatric to adult care.

"The COVID-19 pandemic has provided us with an unexpected chance at truly changing the way endocrinology and diabetes care is delivered far into the future," said task force member Shivani Agarwal, M.D., M.P.H, of the Albert Einstein College of Medicine in Bronx, N.Y. "This manuscript highlights recent strides and reminds us of remaining challenges we must address to sustain innovation."

The task force discusses the challenges to widespread adoption of these new models of care like lack of insurance coverage, technology integration and workforce shortages, and provides potential solutions to foster innovation and create sustainability.

"Embracing new ways of delivering care is going to be important for taking care of large populations of people with complex conditions like diabetes," said Michelle Griffith, M.D., of Vanderbilt University in Nashville, Tenn. "When we use these innovative models appropriately, we can often give the right care for a given situation more efficiently."
-end-
Other members of the task force include: Elizabeth J. Murphy of the University of California in San Francisco in San Francisco, Calif.; M. Carol Greenlee of Western Slope Endocrinology in Grand Junction, Colo.; and Jeffrey Boord of the Parkview Health System in Fort Wayne, Ind.

The manuscript received funding from the National Institute of Diabetes and Digestive and Kidney Diseases.

The manuscript, "Innovations in Diabetes Care for a Better 'New Normal' Beyond COVID-19," was published online, ahead of print.

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at?http://www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.

The Endocrine Society

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.